Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
The start of Donald Trump’s second presidency and Republican control in the 119th Congress raises questions about the future ...
The Capping Prescription Costs Act would cap annual out-of-pocket prescription drug costs per year at $2,000 for individuals ...
We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc.
Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...
State Sen. Teresa Ibach says local Lexington leaders and the Central and Mid-Plains community college areas are working on a ...
The 340B Drug Pricing Program (340B Program) is no stranger to controversy. We have previously covered the ongoing contract pharmacy legal battles ...
Originally priced at $400, the beautiful bedding is now on sale for just $129, an incredible 70% off. The complete set comes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback